Patents by Inventor Junji Matsui

Junji Matsui has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10945990
    Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and eribulin or a pharmaceutically acceptable salt thereof, and the use of the combination therapies for the treatment of cancer.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: March 16, 2021
    Assignees: EISAI R&D MANAGEMENT CO., LTD., MERCK SHARP & DOHME CORP.
    Inventors: Junji Matsui, Gursel Aktan, Vassiliki Karantza, RuiRong Yuan, Yasuhiro Funahashi, Erhan Berrak
  • Publication number: 20200199689
    Abstract: The purpose of the present invention is to provide a method for predicting the effectiveness of an angiogenesis inhibitor in a subject suffering from a tumor. Provided is a method comprising a step of testing for the presence or absence of an a mutation or loss of expression of B-Raf and PTEN in a sample of tumor tissue from the subject. By using the presence or absence of or a mutation or loss of expression of B-Raf and PTEN as an indicator, this method enables the antitumor effectiveness of the angiogenesis inhibitor to be predicted without administering the angiogenesis inhibitor to the subject.
    Type: Application
    Filed: March 4, 2020
    Publication date: June 25, 2020
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Taro Semba, Yusuke Narita, Yukinori Minoshima, Atsumi Yamaguchi, Yusuke Adachi, Kazuhiko Yamada, Junji Matsui, Tadashi Kadowaki, Kentaro Takahashi, Yasuhiro Funahashi
  • Publication number: 20190111022
    Abstract: The present invention provides a method for inhibiting growth of at least one tumor selected from the group consisting of uterine cancer, esophageal cancer, pancreatic cancer, liver cancer, biliary tract cancer, duodenal cancer, lung cancer, kidney cancer, sarcoma, brain tumor, urothelial cancer, thyroid cancer, stomach cancer, and lymphoma in a patient, by administering to the patient a liposome composition comprising eribulin or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: April 26, 2017
    Publication date: April 18, 2019
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Makoto Asano, Junji Matsui
  • Publication number: 20190000797
    Abstract: A novel tumor therapeutic agent for a combination therapy is disclosed. More specifically, a tumor therapeutic agent used for a combination therapy of lenvatinib, ifosfamide, and etoposide is disclosed.
    Type: Application
    Filed: August 18, 2016
    Publication date: January 3, 2019
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Kiyoshi Okamoto, Junji Matsui, Corina Dutcus
  • Publication number: 20190000829
    Abstract: A therapeutic agent for biliary tract cancer comprising 4-[3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy]-7-methoxy-6-quinolinecarboxamide or a pharmacologically acceptable salt thereof is provided.
    Type: Application
    Filed: August 17, 2016
    Publication date: January 3, 2019
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Junji Matsui, Masahiro Matsuki, Akihiko Tsuruoka, Toshiyuki Tamai, Ryo Nakajima, Takuya Suzuki
  • Publication number: 20180209980
    Abstract: Biomarkers are provided that are predictive of a subject's responsiveness to a therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof (e.g., lenvatinib mesylate). The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having cancer (e.g., thyroid cancer, kidney cancer), suspected of having cancer, or at risk of developing cancer.
    Type: Application
    Filed: March 23, 2018
    Publication date: July 26, 2018
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Yasuhiro Funahashi, Tadashi Kadowaki, Junji Matsui, Jason S. Simon, Lucy Xu
  • Patent number: 9969812
    Abstract: The present invention provides an anti-human Notch4 antibody or a Notch4 binding fragment thereof that may have neutralizing activity against human Notch4, as well as a pharmaceutical composition comprising the same as the active ingredient. The present inventors obtained a mouse anti-human Notch4 antibody that has high neutralizing activity and binding affinity towards human Notch4 and determined the complementarity determining region (CDR) sequence of the mouse anti-human Notch4 antibody. This enabled the production of a humanized antibody comprising the variable region of heavy and light chains as well as the CDR sequence of the mouse anti-human Notch4 antibody.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: May 15, 2018
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Yoshimasa Sakamoto, Yusuke Adachi, Junji Matsui, Yu Kato, Yoichi Ozawa, Takanori Abe, Ken Ito, Yuya Nakazawa, Sho Tachino, Katsuhisa Suzuki, Kishan Agarwala, Kana Hoshino, Masahiko Katayama
  • Patent number: 9945862
    Abstract: Biomarkers are provided that are predictive of a subject's responsiveness to a therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof (e.g., lenvatinib mesylate). The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having cancer (e.g., thyroid cancer, kidney cancer), suspected of having cancer, or at risk of developing cancer.
    Type: Grant
    Filed: May 31, 2012
    Date of Patent: April 17, 2018
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Yasuhiro Funahashi, Tadashi Kadowaki, Junji Matsui, Jason S. Simon, Lucy Xu
  • Publication number: 20180071247
    Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and eribulin or a pharmaceutically acceptable salt thereof, and the use of the combination therapies for the treatment of cancer.
    Type: Application
    Filed: March 3, 2016
    Publication date: March 15, 2018
    Applicants: MERCK SHARP & DOHME CORP., Eisai R&D Management Co., Ltd.
    Inventors: Junji MATSUI, Gursel AKTAN, Vassiliki KARANTZA, RuiRong YUAN, Yasuhiro FUNAHASHI, Erhan BERRAK
  • Publication number: 20170191137
    Abstract: The purpose of the present invention is to provide a method for predicting the effectiveness of an angiogenesis inhibitor in a subject suffering from a tumor. Provided is a method comprising a step of testing for the presence or absence of an a mutation or loss of expression of B-Raf and PTEN in a sample of tumor tissue from the subject. By using the presence or absence of or a mutation or loss of expression of B-Raf and PTEN as an indicator, this method enables the antitumor effectiveness of the angiogenesis inhibitor to be predicted without administering the angiogenesis inhibitor to the subject.
    Type: Application
    Filed: March 16, 2017
    Publication date: July 6, 2017
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Taro Semba, Yusuke Narita, Yukinori Minoshima, Atsumi Yamaguchi, Yusuke Adachi, Kazuhiko Yamada, Junji Matsui, Tadashi Kadowaki, Kentaro Takahashi, Yasuhiro Funahashi
  • Publication number: 20170100367
    Abstract: The invention features methods and kits for use in treating cancer in a patient in need thereof by administering eribulin or a pharmaceutically-acceptable salt thereof (e.g., eribulin mesylate) prior to a second agent.
    Type: Application
    Filed: May 27, 2015
    Publication date: April 13, 2017
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Makoto ASANO, Bruce A. LITTLEFIELD, Junji MATSUI, Martin OLIVO, Yoichi OZAWA, Yanke YU
  • Publication number: 20170096493
    Abstract: The present invention provides an anti-human Notch4 antibody or a Notch4 binding fragment thereof that may have neutralizing activity against human Notch4, as well as a pharmaceutical composition comprising the same as the active ingredient. The present inventors obtained a mouse anti-human Notch4 antibody that has high neutralizing activity and binding affinity towards human Notch4 and determined the complementarity determining region (CDR) sequence of said mouse anti-human Notch4 antibody. This enabled the production of a humanized antibody comprising the variable region of heavy and light chains as well as the CDR sequence of said mouse anti-human Notch4 antibody.
    Type: Application
    Filed: December 19, 2016
    Publication date: April 6, 2017
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Yoshimasa Sakamoto, Yusuke Adachi, Junji Matsui, Yu Kato, Yoichi Ozawa, Takanori Abe, Ken Ito, Yuya Nakazawa, Sho Tachino, Katsuhisa Suzuki, Kishan Agarwala, Kana Hoshino, Masahiko Katayama
  • Patent number: 9527921
    Abstract: The present invention provides an anti-human Notch4 antibody or a Notch4 binding fragment thereof that may have neutralizing activity against human Notch4, as well as a pharmaceutical composition comprising the same as the active ingredient. The present inventors obtained a mouse anti-human Notch4 antibody that has high neutralizing activity and binding affinity towards human Notch4 and determined the complementarity determining region (CDR) sequence of the mouse anti-human Notch4 antibody. This enabled the production of a humanized antibody comprising the variable region of heavy and light chains as well as the CDR sequence of the mouse anti-human Notch4 antibody.
    Type: Grant
    Filed: April 14, 2016
    Date of Patent: December 27, 2016
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Yoshimasa Sakamoto, Yusuke Adachi, Junji Matsui, Yu Kato, Yoichi Ozawa, Takanori Abe, Ken Ito, Yuya Nakazawa, Sho Tachino, Katsuhisa Suzuki, Kishan Agarwala, Kana Hoshino, Masahiko Katayama
  • Publication number: 20160347858
    Abstract: The present invention provides an anti-human Notch4 antibody or a Notch4 binding fragment thereof that may have neutralizing activity against human Notch4, as well as a pharmaceutical composition comprising the same as the active ingredient. The present inventors obtained a mouse anti-human Notch4 antibody that has high neutralizing activity and binding affinity towards human Notch4 and determined the complementarity determining region (CDR) sequence of said mouse anti-human Notch4 antibody. This enabled the production of a humanized antibody comprising the variable region of heavy and light chains as well as the CDR sequence of said mouse anti-human Notch4 antibody.
    Type: Application
    Filed: April 14, 2016
    Publication date: December 1, 2016
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Yoshimasa Sakamoto, Yusuke Adachi, Junji Matsui, Yu Kato, Yoichi Ozawa, Takanori Abe, Ken Ito, Yuya Nakazawa, Sho Tachino, Katsuhisa Suzuki, Kishan Agarwala, Kana Hoshino
  • Patent number: 9006256
    Abstract: The present invention provides pharmaceutical compositions and therapeutic methods for treating diseases such as multiple endocrine neoplasia type IIA, multiple endocrine neoplasia type IIB, familial medullary thyroid carcinoma, thyroid carcinoma, papillary thyroid carcinoma, sporadic medullary thyroid carcinoma, Hirschsprung disease, pheochromocytoma, parathyroid hyperplasia and mucosal neuromas of the gastrointestinal tract. The therapeutic methods and pharmaceutical compositions use a RET kinase inhibiting substance, such as 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and pharmacologically acceptable salts thereof, and involve a step of administering the RET kinase inhibiting substance to a patient.
    Type: Grant
    Filed: April 8, 2011
    Date of Patent: April 14, 2015
    Assignee: Eisai R&D Management Co., Ltd.
    Inventor: Junji Matsui
  • Patent number: 9006240
    Abstract: The present invention provides a method of predicting the antitumor effect of an angiogenesis inhibitor. It is possible to predict the antitumor effect of an angiogenesis inhibitor by evaluating the EGF dependency of a tumor cell for proliferation and/or survival and using the EGF dependency as an indicator. Since the antitumor effect of an angiogenesis inhibitor correlates with the EGF dependency of a tumor cell for proliferation and/or survival, the angiogenesis inhibitors is capable of producing excellent antitumor effect when combined with a substance having EGF inhibitory activity.
    Type: Grant
    Filed: August 2, 2006
    Date of Patent: April 14, 2015
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Toshimitsu Uenaka, Yuji Yamamoto, Junji Matsui
  • Patent number: 8969344
    Abstract: The present invention provides a method of predicting the antitumor effect of an angiogenesis inhibitor. It is possible to predict the antitumor effect of an angiogenesis inhibitor by evaluating the EOF dependency of a tumor cell for proliferation and/or survival and using the EGF dependency as an indicator. Since the antitumor effect of an angiogenesis inhibitor correlates with the EGF dependency of a tumor cell for proliferation and/or survival, the angiogenesis inhibitors is capable of producing excellent antitumor effect when combined with a substance having EGF inhibitory activity.
    Type: Grant
    Filed: September 21, 2012
    Date of Patent: March 3, 2015
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Junji Matsui, Yuji Yamamoto, Toshimitsu Uenaka
  • Patent number: 8962650
    Abstract: A therapeutic agent for tumor for combined use of a compound or pharmaceutically acceptable salt thereof represented by Formula (I) and a compound represented by Formula (II): wherein R1 is C1-6 alkyl or C3-8 cycloalkyl, R2 is a hydrogen atom or C1-6 alkoxy, and R3 is a hydrogen atom or a halogen atom, exhibits an excellent antitumor effect compared to cases where these are individually used.
    Type: Grant
    Filed: April 16, 2012
    Date of Patent: February 24, 2015
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Yusuke Narita, Junji Matsui, Yasuhiro Funahashi
  • Publication number: 20140187577
    Abstract: Biomarkers are provided that are predictive of a subject's responsiveness to a therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof (e.g., lenvatinib mesylate). The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having cancer (e.g., thyroid cancer, kidney cancer), suspected of having cancer, or at risk of developing cancer.
    Type: Application
    Filed: May 31, 2012
    Publication date: July 3, 2014
    Applicant: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Yasuhiro Funahashi, Tadashi Kadowaki, Junji Matsui, Jason S. Simon, Lucy Xu
  • Publication number: 20140148483
    Abstract: The purpose of the present invention is to provide a method for predicting the effectiveness of an angiogenesis inhibitor in a subject suffering from a tumor. Provided is a method comprising a step of testing for the presence or absence of an a mutation or loss of expression of B-Raf and PTEN in a sample of tumor tissue from the subject. By using the presence or absence of or a mutation or loss of expression of B-Raf and PTEN as an indicator, this method enables the antitumor effectiveness of the angiogenesis inhibitor to be predicted without administering the angiogenesis inhibitor to the subject.
    Type: Application
    Filed: May 16, 2012
    Publication date: May 29, 2014
    Applicant: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Taro Semba, Yusuke Narita, Yukinori Minoshima, Atsumi Yamaguchi, Yusuke Adachi, Kazuhiko Yamada, Junji Matsui, Tadashi Kadowaki, Kentaro Takahashi, Yasuhiro Funahashi